1. Home
  2. LCTX vs NATH Comparison

LCTX vs NATH Comparison

Compare LCTX & NATH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.68

Market Cap

393.9M

Sector

Health Care

ML Signal

HOLD

Logo Nathan's Famous Inc.

NATH

Nathan's Famous Inc.

N/A

Current Price

$95.22

Market Cap

397.6M

ML Signal

N/A

Company Overview

Basic Information
Metric
LCTX
NATH
Founded
1990
1916
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Restaurants
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
393.9M
397.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
LCTX
NATH
Price
$1.68
$95.22
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$4.25
N/A
AVG Volume (30 Days)
1.3M
49.8K
Earning Date
11-06-2025
11-06-2025
Dividend Yield
N/A
2.10%
EPS Growth
N/A
4.02
EPS
N/A
5.56
Revenue
$10,816,000.00
$154,991,000.00
Revenue This Year
$5.24
N/A
Revenue Next Year
$126.78
N/A
P/E Ratio
N/A
$17.14
Revenue Growth
24.05
7.82
52 Week Low
$0.37
$75.15
52 Week High
$2.09
$118.50

Technical Indicators

Market Signals
Indicator
LCTX
NATH
Relative Strength Index (RSI) 46.00 47.62
Support Level $1.69 $88.67
Resistance Level $1.79 $97.34
Average True Range (ATR) 0.08 3.30
MACD -0.00 0.76
Stochastic Oscillator 43.75 71.64

Price Performance

Historical Comparison
LCTX
NATH

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

About NATH Nathan's Famous Inc.

Nathan's Famous Inc is an owner of fast food franchises in the United States. The company's reportable segment includes the Branded Product Program, Product licensing, Restaurant operations and Corporate. Branded Product Program derives revenue principally from the sale of hot dog products either directly to foodservice operators or to various foodservice distributors who resell the products to foodservice operators. It generates maximum revenue from the Branded Product Program segment. Geographically, it derives a majority of revenue from the United States.

Share on Social Networks: